CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
Global Congress on Bladder Cancer
Oncology Conference Multimedia
View more videos >>
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors
Dr. Konety on Guidelines for the Management of Bladder Cancer
Oncology Conference Articles
Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.
Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond
The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.
Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care
Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.
IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer
Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence
New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC
A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.
Chemotherapy Retains Vital Role in Bladder Cancer Care
Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.
Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma
Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.
Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma
As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.
FDA Approval in HCC, Breakthrough Designation in MCL, and More
Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer
Treatment Goals in Refractory mCRC
FDA Approves Third Trastuzumab Biosimilar
Olaratumab Falls Short in Phase III Soft Tissue Sarcoma Trial
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.